Human Molecular Genetics Advance Access originally published online on April 27, 2006
Human Molecular Genetics 2006 15(11):1876-1883; doi:10.1093/hmg/ddl110
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction
1Department of Pathology and 2Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI 48109, USA
* To whom correspondence should be addressed at: Department of Pathology, University of Michigan Medical School, 1301 Catherine, 4233 Medical Science 1, Ann Arbor, MI 48109, USA. Tel: +1 7349361887; Fax: +1 7347636476; Email: liebermn{at}umich.edu
Received March 3, 2006; Accepted April 17, 2006
The molecular chaperone hsp90 has emerged as an important therapeutic target in cancer and neurodegenerative diseases, including the polyglutamine expansion disorders, because of its ability to regulate the activity, turnover and trafficking of many proteins. For neurodegenerative disorders associated with protein aggregation, the rationale has been that inhibition of hsp90 by geldanamycin and related compounds activates heat shock factor 1 (HSF1) to induce the production of the chaperones hsp70 and hsp40 that promote disaggregation and protein degradation. However, we show here that geldanamycin blocks the development of aggregates of the expanded glutamine androgen receptor (AR112Q) of Kennedy disease in Hsf1–/– mouse embryonic fibroblasts where these chaperones are not induced. Geldanamycin is additionally known to inhibit hsp90-dependent protein trafficking and to promote proteasomal degradation of client proteins. Overexpression of the hsp90 cochaperone p23 also promotes AR112Q degradation, and inhibits both AR trafficking and AR112Q aggregation without altering levels of hsp70 or hsp40. The hsp90-dependent trafficking mechanism has been defined, and it is shown that key immunophilin (IMM) components of the trafficking machinery are present in polyglutamine aggregates in cell and mouse models of Kennedy disease. Our results indicate that inhibition of the hsp90-dependent trafficking mechanism prevents aggregation of the expanded glutamine androgen receptor, thereby opening a variety of novel therapeutic approaches to these neurodegenerative disorders.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Mukherjee, M. Thomas, N. Dadgar, A. P. Lieberman, and J. A. Iniguez-Lluhi Small Ubiquitin-like Modifier (SUMO) Modification of the Androgen Receptor Attenuates Polyglutamine-mediated Aggregation J. Biol. Chem., August 7, 2009; 284(32): 21296 - 21306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Morishima, A. M. Wang, Z. Yu, W. B. Pratt, Y. Osawa, and A. P. Lieberman CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins Hum. Mol. Genet., December 15, 2008; 17(24): 3942 - 3952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Fujikake, Y. Nagai, H. A. Popiel, Y. Okamoto, M. Yamaguchi, and T. Toda Heat Shock Transcription Factor 1-activating Compounds Suppress Polyglutamine-induced Neurodegeneration through Induction of Multiple Molecular Chaperones J. Biol. Chem., September 19, 2008; 283(38): 26188 - 26197. [Abstract] [Full Text] [PDF]
|
|